| 苏旭军,叶建明,钱 洪,程小飞,张 扬.适形调强放疗联合顺铂为基础的化疗对≥5 cm非小细胞肺癌患者生存质量和血清肿瘤标志物的影响[J].,2022,(5):914-918 |
| 适形调强放疗联合顺铂为基础的化疗对≥5 cm非小细胞肺癌患者生存质量和血清肿瘤标志物的影响 |
| Effect of Intensity Modulated Radiation Therapy Combined with Cisplatin Based Chemotherapy on Quality of Life and Serum Tumor Markers in Patients with Non-small Cell Lung Cancer ≥5 cm |
| 投稿时间：2021-06-29 修订日期：2021-07-24 |
| DOI：10.13241/j.cnki.pmb.2022.05.024 |
| 中文关键词: 适形调强放疗 顺铂 非小细胞肺癌 疗效 生存质量 血清肿瘤标志物 |
| 英文关键词: Intensity modulated radiation therapy Cisplatin Non small cell lung cancer Efficacy Quality of life Serum tumor markers |
| 基金项目:江西省卫生计生委科技计划项目（20151172） |
|
| 摘要点击次数: 817 |
| 全文下载次数: 423 |
| 中文摘要: |
| 摘要 目的：探讨适形调强放疗联合顺铂为基础的化疗治疗≥5 cm非小细胞肺癌（NSCLC）的疗效及对生存质量和血清肿瘤标志物的影响。方法：选取2016年1月~2019年1月来我院就诊的60例NSCLC患者（肿瘤直径≥5 cm）。分组方法采用随机数字表法，分为对照组（适形调强放疗）和观察组（适形调强放疗联合顺铂为基础的化疗治疗），各30例。对比两组疗效、生存质量、1年生存率、血清肿瘤标志物和不良反应发生情况。结果：观察组治疗后的生存质量优于对照组（P<0.05）。观察组治疗后的总有效率为63.33%（19/30），高于对照组的36.67%（11/30）（P<0.05）。治疗后，两组神经元烯醇化酶（NSE）、糖类抗原199（CA199）、细胞角蛋白19片段（CYFRA21-1）较治疗前下降，且观察组低于对照组（P<0.05）。观察组的1年生存率66.67%高于对照组36.67%（P<0.05）。两组放射性肺炎、放射性食管炎的发生率组间对比无差异（P>0.05）。观察组的全身不良反应、血液毒性发生率高于对照组（P<0.05）。结论：适形调强放疗联合顺铂为基础的化疗治疗≥5 cm NSCLC患者，疗效较好，可有效控制疾病进展，提高患者生存率。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the efficacy of intensity modulated radiation therapy combined with cisplatin based chemotherapy in the treatment of non-small cell lung cancer (NSCLC)≥5 cm and its influence on the quality of life and serum tumor markers. Methods: 60 patients with NSCLC (tumor diameter≥5 cm) from January 2016 to January 2019 were selected. the patients were randomly divided into control group (IMRT) and observation group (IMRT combined with cisplatin based chemotherapy), 30 cases in each group. The efficacy, quality of life, 1-year survival rate, serum tumor markers and adverse reactions were compared between the two groups. Results: The quality of life in the observation group was better than that in the control group(P<0.05). The total effective rate of the observation group was 63.33% (19/30), which was higher than 36.67% (11/30) of the control group (P<0.05). After treatment, the levels of neuron enolase (NSE), carbohydrate antigen 199 (CA199), cytokeratin 19 fragment (CYFRA21-1) in the observation group were lower than those in the control group(P<0.05). The 1-year survival rate of the observation group was 66.67%, which was higher than 36.67% of the control group(P<0.05). There was no difference in the incidence of radiation pneumonia and radiation esophagitis between the two groups(P>0.05). The incidence of systemic adverse reactions and hematotoxicity in the observation group was higher than that in the control group(P<0.05). Conclusion: Intensity modulated radiation therapy combined with cisplatin based chemotherapy in the treatment of NSCLC patients with≥5 cm is effective, which can effectively control the disease progression and improve the survival rate of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
